CClinicalTrials.gg
Status unknownNCT05273840Updated Jun 9, 2022

Effect of Nutritional Supplements on Clinical Outcomes in Patients With Prediabetes and Obesity

An interventional study of Ivital Control and lifestyle intervention in PreDiabetes and Obesity, sponsored by Ningbo No. 1 Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by Ningbo No. 1 Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2021, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aims to improve blood glucose and weight in patients with prediabetes and obesity through health education, nutritional supplement interventions, clinical evaluation, and close clinical follow-up.100 patients with prediabetes with obesity were randomly divided into 2 groups: life intervention group, nutritional supplement intervention group. All enrolled participants were recommended for routine diabetes lifestyle education according to the "Expert Consensus on Prediabetes Intervention in Adults in China". The duration of the intervention was 3 months. The investigators aimed to compare the differences in weight, glycosylated hemoglobin, lipids and other indicators of the two groups of included populations before and after the intervention. In addition, the investigators are to explore the effects of nutritional supplement interventions on glycolipid metabolism and body weight in prediabetes with obesity.

02

Conditions studied

  • PreDiabetes
  • Obesity

Keywords

  • PreDiabetes
  • Obesity
  • Glycosylated hemoglobin
  • weight
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's planned enrollment of 100 is above the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Ningbo No. 1 Hospital is the lead sponsor of 56 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • According to the American Diabetes Society (ADA) 2010 standard: meet one of the following (1) fasting blood glucose at 100 mg/dl to 125 mg/dl; (2) sugar load 2h blood glucose at 140 mg/dl to 199 mg/dl; (3) glycosylated hemoglobin in 5.7% to 6.4%
  • Body mass index (BMI) ≥ 25 and ≤ 35kg/m2
  • Have lived locally for at least half a year and have a fixed residence
  • No other clinical trials were participated in in the 3 months prior to the trial
  • Mental health, being able to take care of oneself in life

Exclusion criteria

Exclusion Criteria:

  • People with confirmed diabetes
  • Weight change of more than 10% over the past 3 months
  • Pregnant or lactating women, men and women planning to become pregnant within two years, or unwilling and unable to use contraception during the study period (women only)
  • People who are allergic to the ingredients of nutritional supplements
  • Those who have lost weight by any medication (including appetite suppressants such as fluprophenylpropanine, progesterone, laxatives, etc., and diet pills with various Traditional Chinese medicine ingredients) or surgery in the past 3 months
  • Patients who have received medical treatment for the following diseases in the past 3 months: diabetes, cholecystitis, peptic ulcer, inflammatory bowel disease, acute urinary tract infection, hyperthyroidism, etc., or patients with chronic gastrointestinal diseases with symptoms of nausea, vomiting and diarrhea in the past month
  • Suffer from severe organic diseases such as cancer, coronary heart disease, myocardial infarction and stroke
  • Presence of pituitary-adrenal axis dysfunction; secondary obesity due to other diseases (e.g., Cushing syndrome, hypothyroidism, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    life intervention group

    On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given to the patients until the end of the visit.

    Behavioral: lifestyle intervention

  • Experimental
    nutritional supplement intervention group

    On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.

    Dietary Supplement: Ivital Control

Interventions

  • Dietary supplementIvital Control

    Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.

    Also known as: Produced by Fresenius Kabi, Chocolate flavor, Product specifications: 460g (46g*10)

  • Behaviorallifestyle intervention

    Patients will receive lifestyle interventions.

06

What researchers measure

Primary outcomes

  1. the proportions of participants regressing back to normal glucose level

    The normal glucose level was defined as FPG \< 6.1 mmol/L and 2hPG \< 7.8 mmol/L during the OGTT.

    Time frame: 3 months

Secondary outcomes

  1. change in HbA1c

    change in HbA1c

    Time frame: 3 months

  2. body weight

    changes in body weight

    Time frame: 3 months

Other outcomes

  1. changes in waist circumference

    anthropometric parameters

    Time frame: 3 months

  2. changes in hip circumference

    anthropometric parameters

    Time frame: 3 months

  3. changes in neck circumference

    anthropometric parameters

    Time frame: 3 months

  4. changes in visceral fat area

    body composition

    Time frame: 3 months

  5. changes in body fat percentage

    body composition

    Time frame: 3 months

  6. changes in lean mass

    body composition

    Time frame: 3 months

  7. blood lipids

    changes in LDL-cholesterol, HDL-cholesterol

    Time frame: 3 months

  8. changes in triglyceride level (blood lipids)

    changes in triglyceride

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Ningbo First Hospital
    Ningbo, China
    • Li Li · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05273840
Lead sponsor
Ningbo No. 1 Hospital
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
Jun 11, 2021
Primary completion
Oct 2022 (estimated)
Completion
Nov 2022 (estimated)
Last update
Jun 9, 2022

Study contacts

Li Li, Bachelor of Medicine degree
Contact
lilyningbo@163.com
8613757426626

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion